Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIRO for unresectable cutaneous squamous cell carcinoma
ACTRN12618001573246Phase 2Not yet recruiting
- Sponsor
- Metro North Health
- Start
- Nov 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and carboplatin in cutaneous squamous cell carcinoma (cSCC) and cutaneous malignancy, sponsored by Metro North Health. Primary endpoints: Incidence of grade 3 and 4 toxicities and Complete response rate. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
durvalumabcarboplatin
03
Conditions
cutaneous squamous cell carcinoma (cSCC)cutaneous malignancy
Beyond the preview
Go deeper on ACTRN12618001573246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001573246.